Updates in NRG1+ Tumors | Supplements And Featured Publications

Real-World Study Confirms NRG1 Fusions in NSCLC, Supports Afatinib Studies

January 28, 2021

January 28, 2021 - NRG1 fusions are detectable in patients with non–small cell lung cancer, providing a rationale to perform larger, retrospective studies assessing therapeutic outcomes in patients with NRG1 fusion–positive tumors and evaluate afatinib in this patient subgroup.